Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$146.23
▼ $5.60 (-3.7%)
Market data updated: 09/19 07:12 PM
Fundamentals updated: 09/19/2026
News analyzed: 09/19/2026
Market Cap
$14.86B
Day Range
$146.06 - $152.63
52-Week Range
$122.14 - $186.12
Beta
—
Next Earnings
26.10.2026
Support
$146.06
Resistance
$186.12
NBIX is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+0.4% (1Y)
Strengths: 12/28 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
DCF Fair Value
Estimated fair value: $183.94 vs. price $146.23 (+25.8%)
Fair Value
Biggest negative driver
Calmar Ratio (return vs. drawdown)
Calmar: 0.20 (3y annualized return 8.4% / max drawdown 42.9%)
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
57
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
82
Quality
58
Value
62
Momentum
13
Risk
48
Sentiment
92
Fundamental
76
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent coverage of Neurocrine Biosciences focuses on strong analyst support and product momentum. In early September, Morgan Stanley, RBC and Citigroup raised or maintained price targets (to $183, $198 and $253), while presenting at major healthcare conferences. RBC highlights Ingrezza and Crenessity as drivers for H2 and a catalyst‑rich 2027, noting Crenessity’s rapid sales growth in CAH. Overall, media attention centers on positive analyst outlook and the commercial traction of its key products.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Neurocrine Biosciences, Inc.. News trend score: 92. Reason: 9 of the last 20 articles are positive, versus 2 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
23
🎯 Conviction (vs. Emotion)
41
Psychology
98
Fundamentals
76
Technical
13
Valuation
62
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price (3M)
-8%
Market Narrative
41
Fundamental Reality
41
Narrative Gap
+0
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior for NBIX suggests a dominant herding dynamic, where traders align with peer underperformance rather than chasing momentum or sentiment. The narrative gap (6 points) hints at a disconnect between market perception and fundamentals, but the lack of extreme volatility or volume rules out panic or euphoria. Anchoring to support (4.1% above) may reinforce cautious positioning, while minimal FOMO or overconfidence signals a measured approach. The key question remains whether this herding reflects a structural shift or temporary peer-driven weakness.
Updated: 09/09/2026, 06:52 AM
What could change this?
👥 What the crowd believes
"Citigroup raises Neurocrine Biosciences price target to $253"
"FDA accepted Phase 2 trial for Alzheimer’s cognition drug"
"Ingrezza and Crenessity products driving H2 appreciation"
"EPS +114%, P/E 21 vs industry 42, no debt, ROE 19%"
📈 10D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Jesse Livermore — 30/100
🗣️ Why do they disagree?
Based on Bagehot's liquidity focus and Nelson's cycle view, the model estimates NBIX is well positioned in terms of financial stability and near‑oversold conditions, reflected in scores of 100 and 98. Growth‑oriented investors such as Peter Lynch, Philip Fisher and Thorstein Veblen also rate the stock favorably (87, 83, 66), highlighting perceived growth potential and company quality, though they stop short of labeling it a clear long‑term hold. More conservative or market‑efficiency frameworks—Graham’s defensive criteria (37), Graham’s enterprising bar (31), and Livermore’s trend rule (29)—rate the stock poorly, indicating concerns about valuation, safety margins, and price momentum. The middle‑ground scores from Marks, Smith, Housel, and the efficient‑market view (around 50‑63) reflect a consensus that NBIX is modestly attractive but not a standout pick, balancing growth optimism with valuation and cycle cautions.
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 99
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 88
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟢 83
Exceptional company quality by Fisher's standards
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 77
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟢 66
Growth appears aligned with real value creation
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 63
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 62
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 62
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 55
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 55
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 53
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 52
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 38
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 31
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 30
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Based on the last 281 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (0 bullish · 10 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
98.2%
Operating Margin
21.6%
Net Margin
16.7%
EBITDA Margin
21.6%
ROE
14.7%
ROA
10.3%
ROIC
—
EPS
$4.81
Cash
$713.00M
Total Debt
—
Current Ratio
3.39
Debt/Equity
—
How is Fair Value calculated? →
Current Price
$146.23
Estimated Fair Value (DCF)
$183.94
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
+25.8%
🟢 Appears cheap relative to estimated value
Year 1 Growth Rate
24.3%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 24.3% | $930.94M | $854.07M |
| 2 | 18.9% | $1.11B | $931.49M |
| 3 | 13.4% | $1.26B | $969.26M |
| 4 | 8.0% | $1.36B | $960.02M |
| 5 | 2.5% | $1.39B | $902.77M |
Base FCF (last actual year)
$748.70M
Terminal Value
$21.90B
Present Value of Terminal Value
$14.24B
Enterprise Value
$18.85B
Net Debt
$0
Equity Value
$18.85B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$31.74
Tangible Book Value per Share (Tangible NAV)
$31.74
Sentiment based on basic keywords (not AI) — 9 positive, 9 neutral, 2 negative out of the last 20 articles.
Yahoo · 18.9.2026
SeekingAlpha · 15.9.2026
Benzinga · 11.9.2026
SeekingAlpha · 10.9.2026
SeekingAlpha · 9.9.2026
Yahoo · 8.9.2026
MT Newswires · 8.9.2026
Benzinga · 8.9.2026
Benzinga · 3.9.2026
Yahoo · 2.9.2026
PR Newswire · 2.9.2026
Yahoo · 31.8.2026
Zacks · 31.8.2026
SeekingAlpha · 31.8.2026
ChartMill · 29.8.2026
Yahoo · 28.8.2026
Simply Wall St. · 28.8.2026
Yahoo · 27.8.2026
Simply Wall St. · 27.8.2026
Yahoo · 27.8.2026
Neurocrine Biosciences, Inc. (NBIX) currently has a StockIQ AI score of 57/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
NBIX currently scores 57/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, NBIX's estimated fair value is $183.94, which is 25.8% above the current price of $146.23. This is one valuation model among several signals in the fair-value category, not a price target.
NBIX's technical score is 13/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Estimated fair value: $183.94 vs. price $146.23 (+25.8%); Revenue growth (last year): 21.4%; Earnings per share (EPS) growth: 41.9%.
Based on the real signals StockIQ computed: Calmar: 0.20 (3y annualized return 8.4% / max drawdown 42.9%); Price is below the 50-day average; Price is below the 200-day average.
StockIQ has no recorded dividend payment history for NBIX.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 7 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| BENEVICH ERIC | Open Market Sale | 9.9.2026 | 2,154 | -2,154 | $154.61 |
| BENEVICH ERIC | Exercise of Derivative Securities | 9.9.2026 | 3,194 | +3,194 | $43.24 |
| BENEVICH ERIC | Exercise of Derivative Securities | 9.9.2026 | 3,194 | -3,194 | — |
| SHERWIN STEPHEN A | Gift | 2.9.2026 | 1,000 | -1,000 | — |
| Onyia Jude | Gift | 4.8.2026 | 2,409 | -2,409 | — |
| Onyia Jude | Gift | 4.8.2026 | 20,996 | -2,409 | — |
| Norwalk Leslie V | Exercise of Derivative Securities | 29.7.2026 | 842 | +842 | $139.43 |
| Norwalk Leslie V | Exercise of Derivative Securities | 29.7.2026 | 842 | -842 | — |
| Norwalk Leslie V | Exercise of Derivative Securities | 29.7.2026 | 2,430 | +842 | $139.43 |
| Norwalk Leslie V | Exercise of Derivative Securities | 29.7.2026 | 2,140 | -842 | — |
| Norwalk Leslie V | Open Market Sale | 28.7.2026 | 1,250 | -1,250 | $182.01 |
| Norwalk Leslie V | Open Market Sale | 28.7.2026 | 1,588 | -1,250 | $182.01 |
| Delaet Ingrid | Open Market Sale | 10.7.2026 | 4,367 | -4,367 | $181.02 |
| Delaet Ingrid | Exercise of Derivative Securities | 10.7.2026 | 4,367 | -4,367 | — |
| Delaet Ingrid | Exercise of Derivative Securities | 10.7.2026 | 4,367 | +4,367 | $106.02 |
| Delaet Ingrid | Exercise of Derivative Securities | 10.7.2026 | 20,592 | +4,367 | $106.02 |
| Delaet Ingrid | Open Market Sale | 10.7.2026 | 16,225 | -4,367 | $181.02 |
| Delaet Ingrid | Exercise of Derivative Securities | 10.7.2026 | 0 | -4,367 | — |
| Lippoldt Darin | Exercise of Derivative Securities | 9.7.2026 | 10,000 | +10,000 | $81.49 |
| Delaet Ingrid | Exercise of Derivative Securities | 9.7.2026 | 8,433 | -8,433 | — |
| Delaet Ingrid | Exercise of Derivative Securities | 9.7.2026 | 8,433 | +8,433 | $103.52 |
| Lippoldt Darin | Exercise of Derivative Securities | 9.7.2026 | 10,000 | -10,000 | — |
| Lippoldt Darin | Open Market Sale | 9.7.2026 | 10,000 | -10,000 | $179.60 |
| Delaet Ingrid | Open Market Sale | 9.7.2026 | 8,433 | -8,433 | $178.72 |
| Lippoldt Darin | Exercise of Derivative Securities | 9.7.2026 | 64,729 | +10,000 | $81.49 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
5,056,144 shares short as of 2026-08-31 · vs. 4,390,083 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
65.9% of trading volume this week was short selling, vs. 60.9% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology